Physician profile
Igor Gefter
NPI 1528013547
$6,562.49
in general payments reported to CMS, 2019-2025
26 companies · $1,989 in 2025
The $1,989 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,334 · 2020: $129 · 2021: $664 · 2022: $408 · 2023: $913 · 2024: $1,127 · 2025: $1,989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,979 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,979.33 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,901.70 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $740.58 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $507.58 | 2022-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $335.34 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $295.91 | 2019-2025 | Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $223.75 | 2021-2025 | Caplyta |
| Lundbeck LLC | $217.96 | 2019-2025 | Rexulti |
| Allergan, INC. | $215.98 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $182.77 | 2019 | |
| Vanda Pharmaceuticals INC. | $158.78 | 2019-2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $120.76 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $106.89 | 2019-2024 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $80.29 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $63.25 | 2025 | Auvelity, Sunosi |
| Indivior INC. | $60.87 | 2024-2025 | Perseris, Sublocade |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $58.56 | 2019-2020 | |
| Corium, LLC | $56.75 | 2023-2025 | Azstarys |
| Braeburn INC. | $49.93 | 2024-2025 | Brixadi |
| Almatica Pharma LLC | $45.65 | 2023-2025 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $29.88 | 2023 | Quviviq |
| Validus Pharmaceuticals LLC | $25.05 | 2019 | |
| Lilly USA, LLC | $21.50 | 2025 | Kisunla, Amyvid |
| Sage Therapeutics, LLC | $20.80 | 2024 | |
| Avanir Pharmaceuticals, INC. | $14.47 | 2022 | |
| Neos Therapeutics, LP | $13.76 | 2025 | Exxua |
| Shire North American Group INC | $13.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Igor Gefter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.